Walleye Capital LLC Esperion Therapeutics, Inc. Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $27,532 - $41,162	13,630 Added 6.37%	227,630 $610,000
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $156,220 - $659,120	214,000 New	214,000 $639,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $17,952 - $89,760	12,296 New	12,296 $19,000
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $142,304 - $212,282	-26,111 Reduced 3.6%	698,343 $4.68 Million
Q2 2022 Aug 08, 2022	BUY	$4.77 - $6.67 $1.99 Million - $2.79 Million	417,773 Added 136.22%	724,454 $4.61 Million
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $487,412 - $811,381	145,932 Added 90.78%	306,681 $1.42 Million
Q4 2021 Mar 03, 2022	BUY	$4.81 - $11.92 $773,202 - $1.92 Million	160,749 New	160,749 $803,000
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $8,232 - $22,152	-300 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $8,106 - $13,698	-229 Reduced 43.29%	300 $18,000
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $21,212 - $27,682	529 New	529 $25,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $156M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.